Dosage Information Research Feed Research Breakdown Oleoylethanolamide for patients with non-alcoholic fatty liver disease February 5, 2021/#FlawedStudy•#Dietitians•Liver Health•Nonalcoholic Fatty Liver Disease (NAFLD)•Oleoylethanolamide
1d–f). In particular, OEA decreased frustration stress-induced HPF overconsumption in a dose- and time-dependent manner, with the strongest and long-lasting effect observed at the dosage of 10 mg kg−1 i.p. (Fig. 1c). The intermediate dose of OEA (5 mg kg−1 i.p.) ...
The present invention discloses novel synergistic pharmaceutical co-crystals of Metformin or its pharmaceutically acceptable salts and oleoylethanolamide in fixed stoichiometric ratio at lower dosage, with improved residence time thereby increasing the bioavailability and efficacy, as anti- diabetic agent. ...
The present invention discloses novel synergistic pharmaceutical co-crystals of Metformin or its pharmaceutically acceptable salts and oleoylethanolamide in fixed stoichiometric ratio at lower dosage, with improved residence time thereby increasing the bioavailability and efficacy, as anti- diabetic agent. ...
The present invention discloses novel synergistic pharmaceutical co-crystals of Metformin or its pharmaceutically acceptable salts and oleoylethanolamide in fixed stoichiometric ratio at lower dosage, with improved residence time thereby increasing the bioavailability and efficacy, as anti- diabetic agent. ...
The present invention discloses novel synergistic pharmaceutical co-crystals of Metformin or its pharmaceutically acceptable salts and oleoylethanolamide in fixed stoichiometric ratio at lower dosage, with improved residence time thereby increasing the bioavailability and efficacy, as anti- diabetic agent. ...